ANI Pharmaceuticals (ANIP) – Analysts’ Weekly Ratings Changes

ANI Pharmaceuticals (NASDAQ: ANIP) has recently received a number of price target changes and ratings updates:

• 8/11/2026 – ANI Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 8/10/2026 – ANI Pharmaceuticals had its price target lowered by Guggenheim from $124.00 to $119.00. They now have a “buy” rating on the stock.
• 8/10/2026 – ANI Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $91.00 to $90.00. They now have a “hold” rating on the stock.
• 8/8/2026 – ANI Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/16/2026 – ANI Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “hold” rating and a $91.00 price target on the stock.
• 7/10/2026 – ANI Pharmaceuticals had its “buy” rating reaffirmed by Guggenheim. They now have a $124.00 price target on the stock.
• 6/23/2026 – ANI Pharmaceuticals was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president owned 74,424 shares of the company’s stock, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the transaction, the director owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.